系统性红斑狼疮中CD19-CAR T细胞治疗与传统药物治疗应答的差异分子特征
该研究比较了7例SLE患者CD19-CAR T细胞治疗前后外周血单核细胞的伪批量基因表达与30例传统药物治疗缓解期SLE患者全血转录组及31例接受利妥昔单抗、贝利尤单抗或环磷酰胺治疗前后SLE患者的数据。结果显示CD19-CAR T细胞诱导的缓解以补体激活、I型干扰素、DNA损伤应答和细胞死亡通路显著抑制及脂质代谢通路上调为特征,且对干扰素、DNA损伤应答、趋化因子、线粒体和mTOR信号通路的抑制程度大于传统药物。
要点
- CD19-CAR T细胞诱导的缓解以补体激活、I型干扰素、DNA损伤应答和细胞死亡通路显著抑制为特征。
- CD19-CAR T细胞治疗较利妥昔单抗和贝利尤单抗更显著下调I/II型干扰素、DNA损伤应答和趋化因子通路。
- CD19-CAR T细胞治疗较环磷酰胺更显著抑制干扰素、线粒体和mTOR信号通路。
核心结论
- CD19-CAR T细胞治疗可显著抑制SLE关键免疫通路(包括补体激活和I型干扰素应答),并伴随代谢重编程。
- CD19-CAR T细胞治疗后缓解的分子特征不同于传统SLE药物治疗,提示CD19-CAR T细胞诱导了更深刻的生物学改变。
研究设计与样本
- 研究比较了7例SLE患者CD19-CAR T细胞治疗前后外周血单核细胞的伪批量基因表达与30例传统药物治疗缓解期SLE患者全血转录组及31例接受利妥昔单抗、贝利尤单抗或环磷酰胺治疗前和治疗后6个月的SLE患者数据。
- 通路分析采用个体微阵列表达功能分析和基因集富集分析。
主要发现
- 与30例传统药物治疗缓解期SLE患者相比,CD19-CAR T细胞诱导的缓解以补体激活、I型干扰素、DNA损伤应答和细胞死亡通路显著抑制及脂质代谢通路上调为特征。
- 与31例中接受利妥昔单抗和贝利尤单抗治疗的患者相比,CD19-CAR T细胞治疗对I/II型干扰素、DNA损伤应答和趋化因子通路的下调程度更大。
- 与31例中接受环磷酰胺治疗的患者相比,CD19-CAR T细胞治疗对干扰素、线粒体和哺乳动物雷帕霉素靶蛋白信号通路的抑制程度更大。
关键数值与推荐
- CD19-CAR T细胞治疗组7例SLE患者,传统药物治疗缓解组30例SLE患者,利妥昔单抗/贝利尤单抗/环磷酰胺治疗组共31例SLE患者(治疗前和治疗后6个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Early trials of CD19-chimeric antigen receptor (CAR) T cell therapy in systemic lupus erythematosus (SLE) show promise, but the molecular mechanisms underlying its disease-modifying effects remain unclear. We aimed to compare biological profiles and alterations following CD19-CAR T cell versus standard pharmacotherapy in SLE. METHODS: Pseudo-bulk gene expression derived from single-cell RNA sequencing of peripheral blood mononuclear cells from 7 SLE patients before and after CD19-CAR T cell therapy was compared with whole-blood transcriptome data from 30 SLE patients in remission on standard pharmacotherapy and 31 SLE patients before and 6 months after treatment with rituximab, belimumab, or cyclophosphamide. Pathway analysis was conducted using Functional Analysis of Individual Microarray Expression and gene set enrichment analysis. RESULTS: CD19-CAR T cell-induced remission was characterised by marked suppression of complement activation, type I interferon, DNA damage response (DDR), and cell death pathways compared with remission following conventional pharmacotherapy, alongside an upregulation of lipid metabolism pathways. Compared with rituximab and belimumab, CD19-CAR T cell therapy induced greater downregulation of type I/II interferon, DDR, and chemokine pathways. Compared with cyclophosphamide, CD19-CAR T cell therapy induced greater suppression of interferon, mitochondrial, and mammalian target of rapamycin signalling pathways. CONCLUSIONS: CD19-CAR T cell therapy induces substantial suppression of key immunological pathways involved in SLE, including complement activation and type I interferon responses, accompanied by a metabolic reprogramming. Molecular profiles of remission after CD19-CAR T cell therapy differ from those induced by conventional SLE pharmacotherapy, suggesting more profound CD19-CAR T cell-induced biological alterations.
引用
- Garantziotis P, Beretta L, Lindblom J, et al. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann Rheum Dis. 2025. PMID: 40701862. doi:10.1016/j.ard.2025.06.2132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。